Friday, October 31, 2025 – A framework published by the European Association for the Study of Obesity (EASO) that addresses the pharmacological treatment of obesity and its complications. This framework proposes a new treatment algorithm that goes beyond solely focusing on weight loss,…
Saturday, October 18, 2025 – Weight-loss surgery dramatically outperformed GLP-1 medications in improving longevity and reducing heart, kidney, and eye complications for people with obesity and diabetes. Over 10 years, patients lost far more weight and required fewer medications. Experts say surgery continues to offer survival advantages even in the age of potent obesity drugs.
Sunday, August 3, 2025 – The provided source explores the increasing use of GLP-1 receptor agonists like semaglutide and liraglutide in individuals with HIV. It highlights that these medications are beneficial for addressing obesity and metabolic syndrome, common issues exacerbated by antiretroviral therapy, by…
Sunday, August 3, 2025 – A Washington Post article talks about the Trump administration experiment to expand Medicare and Medicaid coverage for GLP-1 weight loss drugs like Ozempic, potentially benefiting millions of Americans struggling with obesity. This initiative, a reversal of a previous…
Friday, August 1, 2025 – The provided text describes glucagon-like peptide-1 (GLP-1), detailing its production and the wide array of organs and systems it affects. Primarily, GLP-1 is generated in the intestinal L-cells and the brainstem’s nucleus of the solitary tract (NTS).…
Thursday, July 31, 2025 – This JAMA article provides comprehensive guidance for clinicians on integrating diet and physical activity when prescribing GLP-1 receptor agonists for weight management. It outlines strategies for monitoring and managing both insufficient and excessive weight loss, emphasizing individualized approaches.…
Saturday, July 26, 2025 – This patient-focused guide from JAMA Internal Medicine provides essential information for individuals utilizing GLP-1 medications for weight loss. It outlines the medications’ functions and offers practical dietary advice through a “MEAL” plan, emphasizing muscle maintenance, energy balance, side effect avoidance, and adequate liquid intake.…
Wednesday, July 23, 2025 – The practice of compounding pharmacies adding various supplements to GLP-1 receptor agonist formulations like semaglutide or tirzepatide is very common in the United States. These additions, which often include vitamins, amino acids, and other compounds, are marketed…
Tuesday, July 22, 2025 – “FDA Regulatory Failures in Enforcing Limits on GLP-1 Compounding Puts Patients at Risk,” critically examines the Food and Drug Administration’s (FDA) oversight of compounded GLP-1 medications. It highlights how temporary shortages of these drugs led to a…
Sunday, July 20, 2025 – A systematic review investigating the relationship between adiposity measures and the risk of developing colorectal cancer (CRC), building upon existing research that often relies solely on Body Mass Index (BMI). The review synthesizes findings from fifteen articles across ten…